

1912 Rt 35 S, Ste 203, Oakhurst, NJ 07755 **P** 732 389 1530 | **F** 732 389 0352 **Courier P** 732 508 9154 genesislaboratory.com

Use)

Primarius Pathology

	Time Specimen Col		Received		
Accession Number Practice Name Practic		Time	Received		
		Time			
	NA IEN	Dunation Comba	at Information		
Jidening Friysicians		Practice Contact			
	⊔		City, State, Zip		
		Fax			
Pat (Currently Not Accepti	tient and Insurance	Information Medicaid Plans - Contract Per	nding)		
First Name	Last Name	Middle I	nitial Gender*		
Address Line 1 Addre	ess Line 2	City	State Zip		
DOBCell/	Home Phone	Em	nail		
Gender Identity*Race*	Ethnicity*	Sexu	al Orientation*		
Insured's Name	Relationship to Patie	ent Social	Security #		
Home Phone Cell Phone		DOB	Gender		
Primary Insurance					
Group # ID#					
Address State Zip		SS	Zip		
City State Zip	City _	State	ZIP		
Genesis Respiratory Pathogen Panel (Including COVID-19) (UTM Swab) (See back for details.) COVID-19 + Influenza A & B, and RSV Panel (UTM Swab) COVID-19 ONLY (SARS-CoV-2 PCR Assay) (UTM Swab) Genesis Expanded Respiratory Pathogen Panel** (UTM Swab) (See back for details.) **Please note that an immunodeficiency diagnosis code must be selected in order for this test to be performed. If an appropriate immunodeficiency code is not selected, testing will automatically be reflexed to the "Genesis Respiratory Pathogen Panel".					
ICD-10 Codes					
COVID-19 CODES ARE LISTED BELOW AND MUST BE CHEC	CKED OFF	Immunodeficie	ncy ICD-10 Codes		
J06.9 Acute upper respiratory infection, unspecified U07.1 COVID-19 virus identified D81.9 Combined immunodeficiency, unspecified D83.8 Other common variable immunodeficiencies D83.9 Common variable immunodeficiency, unspecified R06.02 Shortness of breath J20.8 Acute bronchitis due to other specified organisms D84.821 Immunodeficiency due to drugs D84.89 Other immunodeficiencies R06.03 Acute respiratory distress J22 Unspecified acute lower repiratory infection D84.89 Other immunodeficiencies D84.9 Immunodeficiency, unspecified Z20.828 Exposure to other viral communicable diseases D84.9 Immunodeficiency, unspecified D84.9 Immunodefi					
**For Genesis Expanded Respiratory Pathogen Panel, there must be <u>at least one</u> of the immunodeficiency codes in addition to the primary diagnosis code.					
			iza Conocia Laboratory Managament		
This test is medically necessary for the diagnosis or detection of a dis impairment, symptom, syndrome or disorder. The results will determined medical management and treatment decisions. The person listed as provider is authorized by law to order the test(s) requested herein.	sease, illness, Par ine my patient's to	tient Authorization: I hereby author	rize Genesis Laboratory Management opany for above services and appeal if		

Genesis Respiratory Pathogen Panel

Viruses

Adenovirus
COVID-19 (SARS-CoV-2)
Human Metapneumovirus
Influenza A virus/Influenza B virus Pan

Respiratory syncytial virus

Bacteria

Bordetella pan (bronchiseptica, parapertussis, pertussis) Bordetella pertussis Chlamydia pneumoniae

Mycoplasma pneumoniae Legionella pneumophila

COVID-19 + Influenza A & B, and RSV Panel	COVID-19 ONLY	Group A Streptococcus
COVID-19 (SARS-CoV-2) Influenza A	COVID-19 (SARS-CoV-2)	Streptococcus pyogenes
Influenza B Respiratory Syncytial Virus (RSV)		

Genesis Expanded Respiratory Pathogen Panel

Viruses

Adenovirus Influenza A virus A/H3
Coronavirus 229E Influenza A virus A/H1-2009
Coronavirus HKU1 Influenza B virus

Coronavirus NL63 Parainfluenza virus 1
Coronavirus OC43 Parainfluenza virus 2
COVID-19 (SARS-CoV-2) Parainfluenza virus 3
Human Metapneumovirus Parainfluenza virus 4
Human Rhinovirus/Enterovirus Respiratory syncytial virus

Influenza A virus
Influenza A virus A/H1

Bacteria

Bordetella pan (bronchiseptica, parapertussis, pertussis) Bordetella pertussis Chlamydia pneumoniae Mycoplasma pneumoniae

**For Genesis Expanded Respiratory Pathogen Panel, there must be <u>at least one</u> of the immunodeficiency codes in addition to the primary diagnosis code.

COVID-19

Information about COVID-19 (SARS-CoV-2 PCR Assay)

PLEASE NOTE: Testing was performed using the TaqPath COVID-19 Combo Kit and/or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. Positive results do not rule out co-infection with organisms not included in the TaqPath COVID-19 Combo Kit and/or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. The agent detected may not be the definite cause of this disease. This assay is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA). This test is only authorized for the duration of time of the declaration and for the detection of SARSCoV-2 RNA virus and/or diagnosis of COVID-19 infection under section 564 (b)(1) of the act, 21 U.S.C.360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.

A Positive result indicates the presence of SARS-CoV-2 RNA but does not exclude bacterial infection and/or coinfection with other viruses. The agent detected may not be the definitive cause of disease. This result should be combined with clinical observation, patient history, and epidemiological information for patient management decisions.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment and other patient management decisions. Negative results must be used in conjunction with clinical observation, patient history, and epidemiological information for patient management decisions.